Close

Form 10-Q Pharmagreen Biotech Inc. For: Jun 30

August 17, 2022 2:50 PM EDT

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q 

     QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2022

 

or

 

     TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from __________ to __________

 

000-56090

Commission File Number

 

PHARMAGREEN BIOTECH INC.

(Exact name of registrant as specified in its charter)

 

Nevada

 

98-0491567

(State or other jurisdiction of

incorporation or organization) 

 

(I.R.S. Employer

Identification No.)

 

2987 Blackbear Court, Coquitlam, British Columbia

 

V3E 3A2

(Address of principal executive offices) 

 

(Zip Code)

 

702-803-9404

(Registrant’s telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes      ☐ No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☐ Yes       ☒ No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act:

 

Large accelerated filer

Non-accelerated filer

Accelerated filer

Smaller reporting company

 

 

Emerging Growth

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes      ☒ No

 

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PRECEDING FIVE YEARS

 

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. ☐ Yes      ☐ No

 

APPLICABLE ONLY TO CORPORATE ISSUERS:

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date. As of August 15, 2022, we had 424,421,269 shares of common stock issued and outstanding.

 

 

 

 

TABLE of CONTENTS

 

PART I—FINANCIAL INFORMATION

 

 

 

 

 

 

 

Item 1. Financial Statements

 

3

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

18

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

21

 

Item 4. Controls and Procedures

 

21

 

 

 

 

 

PART II—OTHER INFORMATION

 

 

 

 

 

 

 

Item 1. Legal Proceedings

 

22

 

Item 1A. Risk Factors

 

22

 

Item 2. Unregistered Sales of Securities and Use of Proceeds

 

22

 

Item 3. Defaults Upon Senior Securities

 

23

 

Item 4. Mine Safety Disclosure

 

23

 

Item 5. Other Information

 

23

 

Item 6. Exhibits

 

23

 

SIGNATURES

 

25

 

    

 
2

Table of Contents

 

PART I—FINANCIAL INFORMATION

 

Item 1. Financial Statements.

 

PHARMAGREEN BIOTECH INC.

 

Condensed Consolidated Financial Statements

 

For the Nine Months Ended June 30, 2022

 

(Expressed in U.S. Dollars)

 

(Unaudited)

 

 
3

Table of Contents

 

PHARMAGREEN BIOTECH INC.

Condensed Consolidated Balance Sheets

(Expressed in U.S. dollars)

 

 

 

June 30,

2022

 

 

September 30,

2021

 

 

 

 

 

 

$ $

 

 

 

(unaudited)

 

 

 

 

Assets

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash

 

 

24,262

 

 

 

25,300

 

Amounts receivable

 

 

316

 

 

 

290

 

Prepaid expenses and deposits (Notes 11 and 12)

 

 

166,592

 

 

 

347,491

 

 

 

 

 

 

 

 

 

 

Total assets

 

 

191,170

 

 

 

373,081

 

 

 

 

 

 

 

 

 

 

Liabilities and Stockholders’ Deficit

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accounts payable and accrued liabilities (Notes 3 and 7)

 

 

731,287

 

 

 

659,437

 

Advances from Alliance Growers Corp. (Note 12(a))

 

 

58,216

 

 

 

59,122

 

Loans payable (Note 4)

 

 

40,000

 

 

 

40,000

 

Convertible notes – current portion, net of unamortized discount of $10,805 and $nil, respectively (Note 5)

 

 

210,029

 

 

 

190,834

 

Derivative liabilities (Notes 5 and 6)

 

 

306,591

 

 

 

472,003

 

Due to related parties (Note 7)

 

 

644,568

 

 

 

605,019

 

 

 

 

 

 

 

 

 

 

Total current liabilities

 

 

1,990,691

 

 

 

2,026,415

 

 

 

 

 

 

 

 

 

 

Loans payable (Note 4)

 

 

31,049

 

 

 

31,532

 

Loans payable to related parties (Note 7)

 

 

92,692

 

 

 

-

 

Convertible notes, net of unamortized discount of $12,591 and $19,233, respectively (Note 5)

 

 

14,476

 

 

 

7,834

 

 

 

 

 

 

 

 

 

 

Total liabilities

 

 

2,128,908

 

 

 

2,065,781

 

 

 

 

 

 

 

 

 

 

Stockholders’ deficit

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Preferred stock  Authorized: 1,000,000 shares, $0.001 par value; 10,000 shares issued and outstanding

 

 

10

 

 

 

10

 

Common stock  Authorized: 2,000,000,000 shares, $0.001 par value; 424,421,269 and 381,171,269 shares issued and outstanding, respectively (Note 8)

 

 

424,421

 

 

 

381,171

 

Common stock issuable

 

 

18,692

 

 

 

-

 

Additional paid-in capital (Note 8)

 

 

10,117,722

 

 

 

9,680,572

 

Accumulated other comprehensive income (loss)

 

 

12,574

 

 

 

(8,378)

Accumulated deficit

 

 

(12,464,499)

 

 

(11,699,417)

 

 

 

 

 

 

 

 

 

Total Pharmagreen Biotech Inc. stockholders’ deficit

 

 

(1,891,080)

 

 

(1,646,042)

 

 

 

 

 

 

 

 

 

Non-controlling interest

 

 

(46,658)

 

 

(46,658)

 

 

 

 

 

 

 

 

 

Total stockholders’ deficit

 

 

(1,937,738)

 

 

(1,692,700)

 

 

 

 

 

 

 

 

 

Total liabilities and stockholders’ deficit

 

 

191,170

 

 

 

373,081

 

  

Nature of business and continuance of operations (Note 1)

 

(The accompanying notes are an integral part of these condensed consolidated financial statements)

 

 
4

Table of Contents

   

PHARMAGREEN BIOTECH INC.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Expressed in U.S. dollars)

(Unaudited)

 

 

 

Three months ended

June 30,

2022

$

 

 

Three months ended

June 30,

2021

$

 

 

Nine months ended

June 30,

2022

$

 

 

Nine months ended

June 30,

2021

$

 

Expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Consulting fees (Note 7)

 

 

198,081

 

 

 

190,794

 

 

 

761,972

 

 

 

296,987

 

Foreign exchange loss (gain)

 

 

12,310

 

 

 

(3,044)

 

 

9,229

 

 

 

(16,951)

General and administrative

 

 

16,345

 

 

 

20,716

 

 

 

64,462

 

 

 

64,376

 

Professional fees

 

 

10,186

 

 

 

18,829

 

 

 

53,760

 

 

 

111,788

 

Salaries and wages

 

 

4,296

 

 

 

5,085

 

 

 

14,315

 

 

 

14,753

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total expenses

 

 

241,218

 

 

 

232,380

 

 

 

903,738

 

 

 

470,953

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss before other income (expenses)

 

 

(241,218)

 

 

(232,380)

 

 

(903,738)

 

 

(470,953)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other income (expense)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accretion of discount on convertible notes (Note 5)

 

 

(6,156)

 

 

(1,179)

 

 

(10,848)

 

 

(86,801)

Interest and finance costs (Note 4 and 5)

 

 

(10,757)

 

 

(10,087)

 

 

(30,919)

 

 

(673,124)

Gain (loss) on change in fair value of derivative liabilities (Note 6)

 

 

510,066

 

 

 

101,418

 

 

 

180,423

 

 

 

(3,083,420)

Gain on settlement on convertible notes

 

 

-

 

 

 

-

 

 

 

-

 

 

 

613,526

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total other income (expense)

 

 

493,153

 

 

 

90,152

 

 

 

138,656

 

 

 

(3,229,819)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss)

 

 

251,935

 

 

 

(142,228)

 

 

(765,082)

 

 

(3,700,772)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Less: net loss attributable to non-controlling interest

 

 

-

 

 

 

83

 

 

 

-

 

 

 

128

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) attributable to Pharmagreen Biotech Inc.

 

 

251,935

 

 

 

(142,145)

 

 

(765,082)

 

 

(3,700,644)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Comprehensive income (loss)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Foreign currency translation gain (loss)

 

 

40,885

 

 

 

(13,215)

 

 

20,952

 

 

 

(68,414)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Comprehensive income (loss) attributable to Pharmagreen Biotech Inc.

 

 

292,820

 

 

 

(155,360)

 

 

(744,130)

 

 

(3,769,058)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic income (loss) per share attributable to Pharmagreen Biotech Inc. stockholders

 

 

0.00

 

 

 

(0.00)

 

 

(0.00)

 

 

(0.01)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted income (loss) per share attributable to Pharmagreen Biotech Inc. stockholders

 

 

0.00

 

 

 

(0.00)

 

 

(0.00)

 

 

(0.01)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average number of shares outstanding used in the calculation of net income (loss) per share attributable to Pharmagreen Biotech Inc.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

406,566,324

 

 

 

351,763,390

 

 

 

395,041,232

 

 

 

271,420,624

 

Diluted

 

 

613,471,911

 

 

 

351,763,390

 

 

 

395,041,232

 

 

 

271,420,624

 

     

(The accompanying notes are an integral part of these condensed consolidated financial statements)

 

 
5

Table of Contents

 

PHARMAGREEN BIOTECH INC.

Condensed Consolidated Statements of Stockholders’ Deficit

(Expressed in U.S. dollars)

(Unaudited)

 

 

 

Preferred stock

 

 

Common stock

 

 

Common stock

 

 

Additional paid-in

 

 

Accumulated

other

comprehensive income

 

 

 

 

Non -controlling

 

 

Total stockholders’

 

 

 

Number of shares

 

 

Amount

$ 

 

 

Number of shares

 

 

Amount

 

$

 

 

issuable

 

$

 

 

capital

 

$

 

 

(loss)

 

$

 

 

Deficit

 

$

 

 

interest

 

$

 

 

deficit

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, September 30, 2020

 

 

 

 

 

-

 

 

 

95,806,289

 

 

 

95,806

 

 

 

180,000

 

 

 

3,967,261

 

 

 

36,679

 

 

 

(7,167,346)

 

 

(46,505)

 

 

(2,934,105)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of units for cash

 

 

 

 

 

-

 

 

 

5,400,000

 

 

 

5,400

 

 

 

-

 

 

 

21,600

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

27,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of preferred shares for cash

 

 

10,000

 

 

 

10

 

 

 

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

10

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock pursuant to the conversion of convertible notes

 

 

 

 

 

-

 

 

 

144,315,380

 

 

 

144,316

 

 

 

(180,000)

 

 

1,647,737

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

1,612,053

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock for services

 

 

 

 

 

-

 

 

 

90,000

 

 

 

90

 

 

 

-

 

 

 

1,265

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

1,355

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Foreign currency translation loss

 

 

 

 

 

-

 

 

 

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(42,455)

 

 

-

 

 

 

-

 

 

 

(42,455)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss for the period

 

 

 

 

 

-

 

 

 

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(417,109)

 

 

(1)

 

 

(417,110)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, December 31, 2020

 

 

10,000

 

 

 

10

 

 

 

245,611,669

 

 

 

245,612

 

 

 

-

 

 

 

5,637,863

 

 

 

(5,776)

 

 

(7,584,455)

 

 

(46,506)

 

 

(1,753,252)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of units for cash

 

 

 

 

 

-

 

 

 

17,411,250

 

 

 

17,411

 

 

 

6,113

 

 

 

72,701

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

96,225

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock pursuant to the conversion of convertible notes

 

 

 

 

 

-

 

 

 

84,845,100

 

 

 

84,845

 

 

 

-

 

 

 

2,848,372

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

2,933,217

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock for services

 

 

 

 

 

-

 

 

 

300,000

 

 

 

300

 

 

 

-

 

 

 

7,020

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

7,320

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Foreign currency translation loss

 

 

 

 

 

-

 

 

 

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(12,744)

 

 

-

 

 

 

-

 

 

 

(12,744)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss for the period

 

 

 

 

 

-

 

 

 

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(3,141,390)

 

 

(44)

 

 

(3,141,434)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, March 31, 2021

 

 

10,000

 

 

 

10

 

 

 

348,168,019

 

 

 

348,168

 

 

 

6,113

 

 

 

8,565,956

 

 

 

(18,520)

 

 

(10,725,845)

 

 

(46,550)

 

 

(1,870,668)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of units for cash

 

 

 

 

 

-

 

 

 

6,961,250

 

 

 

6,961

 

 

 

(6,113)

 

 

62,585

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

63,433

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares issuable for services

 

 

 

 

 

-

 

 

 

 

 

 

-

 

 

 

121,500

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

121,500

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Foreign currency translation loss

 

 

 

 

 

-

 

 

 

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(13,215)

 

 

-

 

 

 

-

 

 

 

(13,215)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income for the period

 

 

 

 

 

-

 

 

 

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(142,145)

 

 

(83)

 

 

(142,228)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, June 30, 2021

 

 

10,000

 

 

 

10

 

 

 

355,129,269

 

 

 

355,129

 

 

 

121,500

 

 

 

8,628,541

 

 

 

(31,735)

 

 

(10,867,990)

 

 

(46,633)

 

 

(1,841,178)

  

(The accompanying notes are an integral part of these condensed consolidated financial statements)

 

 
6

Table of Contents

 

PHARMAGREEN BIOTECH INC.

Condensed Consolidated Statements of Stockholders’ Deficit (continued)

(Expressed in U.S. dollars)

(Unaudited)

  

 

 

 

Preferred stock

 

 

Common stock

 

 

Common stock

 

 

Additional paid-in

 

 

Accumulated

other

comprehensive income

 

 

Accumulated

 

 

Non -controlling

 

 

Total stockholders’

 

 

 

 

Number of shares

 

 

 

Amount

 $

 

 

 

Number of shares

 

 

 

Amount

$ 

 

 

issuable

 $

 

 

capital

 $

 

 

(loss)

$ 

 

 

deficit

$ 

 

 

interest

 $

 

 

deficit

 

 

Balance, September 30, 2021

 

 

10,000

 

 

 

10

 

 

 

381,171,269

 

 

 

381,171

 

 

 

-

 

 

 

9,680,572

 

 

 

(8,378)

 

 

(11,699,417)

 

 

(46,658)

 

 

(1,692,700)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock for cash, net of issuance costs

 

 

 

 

 

-

 

 

 

4,000,000

 

 

 

4,000

 

 

 

-

 

 

 

88,000

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

92,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Foreign currency translation loss

 

 

 

 

 

-

 

 

 

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(2,463)

 

 

-

 

 

 

-

 

 

 

(2,463)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income for the period

 

 

 

 

 

-

 

 

 

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

18,724

 

 

 

-

 

 

 

18,724

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, December 31, 2021

 

 

10,000

 

 

 

10

 

 

 

385,171,269

 

 

 

385,171

 

 

 

-

 

 

 

9,768,572

 

 

 

(10,841)

 

 

(11,680,693)

 

 

(46,658)

 

 

(1,584,439)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock for cash

 

 

 

 

 

-

 

 

 

1,450,000

 

 

 

1,450

 

 

 

-

 

 

 

25,050

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

26,500

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock for services

 

 

 

 

 

-

 

 

 

10,600,000

 

 

 

10,600

 

 

 

-

 

 

 

198,100

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

208,700

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Foreign currency translation loss

 

 

 

 

 

-

 

 

 

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(17,470)

 

 

-

 

 

 

-

 

 

 

(17,470)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss for the period

 

 

 

 

 

-

 

 

 

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(1,035,741)

 

 

-

 

 

 

(1,035,741)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, March 31, 2022

 

 

10,000

 

 

 

10

 

 

 

397,221,269

 

 

 

397,221

 

 

 

-

 

 

 

9,991,722

 

 

 

(28,311)

 

 

(12,716,434)

 

 

(46,658)

 

 

(2,402,450)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock for services

 

 

 

 

 

-

 

 

 

7,000,000

 

 

 

7,000

 

 

 

-

 

 

 

77,700

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

84,700

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of units for cash

 

 

 

 

 

-

 

 

 

20,200,000

 

 

 

20,200

 

 

 

-

 

 

 

48,300

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

68,500

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common stock issuable for services

 

 

 

 

 

-

 

 

 

 

 

 

-

 

 

 

18,692

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

18,692

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Foreign currency translation income

 

 

 

 

 

-

 

 

 

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

40,885

 

 

 

-

 

 

 

-

 

 

 

40,885

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income for the period

 

 

 

 

 

-

 

 

 

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

251,935

 

 

 

-

 

 

 

251,935

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, June 30, 2022

 

 

10,000

 

 

 

10

 

 

 

424,421,269

 

 

 

424,421

 

 

 

18,692

 

 

 

10,117,722

 

 

 

12,574

 

 

 

(12,464,499)

 

 

(46,658)

 

 

(1,937,738)

  

(The accompanying notes are an integral part of these condensed consolidated financial statements)

 

 
7

Table of Contents

     

PHARMAGREEN BIOTECH INC.

Condensed Consolidated Statements of Cash Flows

(Expressed in U.S. dollars)

(Unaudited)

 

 

 

Nine months

ended

June 30,

2022

$

 

 

Nine months

ended

June 30,

2021

$

 

 

 

 

 

 

 

 

OPERATING ACTIVITIES

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

(765,082)

 

 

(3,700,772)

 

 

 

 

 

 

 

 

 

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Accretion of discount on convertible notes

 

 

10,848

 

 

 

86,801

 

Financing fees and default penalties

 

 

-

 

 

 

673,124

 

Gain on settlement of convertible note

 

 

-

 

 

 

(613,526)

(Gain) loss on change in fair value of derivative liabilities

 

 

(180,423)

 

 

3,083,420

 

Common stock issued or issuable for services

 

 

312,092

 

 

 

130,175

 

 

 

 

 

 

 

 

 

 

Changes in non-cash operating assets and liabilities:

 

 

 

 

 

 

 

 

Accounts receivable

 

 

(26)

 

 

207

 

Prepaid expenses and deposits

 

 

180,899

 

 

 

3,754

 

Accounts payable and accrued liabilities

 

 

71,850

 

 

 

120,273

 

Due to related parties

 

 

35,533

 

 

 

65,307

 

 

 

 

 

 

 

 

 

 

Net cash used in operating activities

 

 

(334,309)

 

 

(151,237)

 

 

 

 

 

 

 

 

 

FINANCING ACTIVITIES

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Proceeds from issuance of convertible note

 

 

30,000

 

 

 

-

 

Proceeds from issuance of units

 

 

75,000

 

 

 

186,725

 

Proceeds from issuance of preferred shares

 

 

-

 

 

 

10

 

Proceeds from issuance of common stock, net of issuance costs

 

 

112,000

 

 

 

-

 

Proceeds from loans from related party

 

 

111,554

 

 

 

33,646

 

Repayment of loans from related parties

 

 

(14,846)

 

 

-

 

 

 

 

 

 

 

 

 

 

Net cash provided by financing activities

 

 

313,708

 

 

 

220,381

 

 

 

 

 

 

 

 

 

 

Effect of foreign exchange rate changes on cash

 

 

19,563

 

 

 

(62,122)

 

 

 

 

 

 

 

 

 

Change in cash

 

 

(1,038)

 

 

7,022

 

 

 

 

 

 

 

 

 

 

Cash, beginning of period

 

 

25,300

 

 

 

12,196

 

 

 

 

 

 

 

 

 

 

Cash, end of period

 

 

24,262

 

 

 

19,218

 

 

 

 

 

 

 

 

 

 

Non-cash investing and financing activities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common shares issued for settlement of convertible notes

 

 

-

 

 

 

4,545,270

 

Derivative liability upon issuance of convertible notes

 

 

15,011

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Supplemental disclosures:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest paid

 

 

-

 

 

 

-

 

Income taxes paid

 

 

-

 

 

 

-

 

  

(The accompanying notes are an integral part of these condensed consolidated financial statements)

 

 
8

Table of Contents

 

PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

June 30, 2022

(Expressed in U.S. dollars)

(Unaudited)

 

1. Nature of Business and Continuance of Operations

 

Pharmagreen Biotech Inc. (“the Company”) was incorporated under the laws of the State of Nevada, U.S. on November 26, 2007, under the name Azure International, Inc. On October 30, 2008, and effective as of the same date, the Company filed Articles of Merger (“Articles”) with the Secretary of State of the State of Nevada, to effect a merger by and between Air Transport Group Holdings, Inc., a Nevada corporation and Azure International, Inc. As a result of the merger, the Company changed its name to Air Transport Group Holdings, Inc. The Company was previously in the business of providing technical advisory and appraisals to the aircraft and aviation business as well as providing sourcing for aircraft leases and parts. Pursuant to a Share Exchange Agreement with WFS Pharmagreen Inc. (“WFS”) on May 2, 2018, the Company changed its name to Pharmagreen Biotech Inc. and changed its principal business to the production of starter plantlets for the North American high CBD hemp and medical cannabis industries through the application of the proprietary plant tissue culture in vitro process called “Chibafreen”. This proprietary process will produce plantlets that will be genetically identical and free of pests and disease free with consistent and certifiable constituent properties.

 

Going Concern

 

These condensed consolidated financial statements have been prepared on the going concern basis, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. As at June 30, 2022, the Company has not earned any revenues from operations, has a working capital deficit of $1,799,521, and has an accumulated deficit of $12,464,499. During the nine months ended June 30, 2022, the Company used cash flows for operations of $334,309. Furthermore, the Company has defaulted on convertible notes. These factors raise substantial doubt upon the Company’s ability to continue as a going concern. These condensed consolidated financial statements do not reflect any adjustments that may be necessary if the Company is unable to continue as a going concern.

 

The outbreak of the novel coronavirus COVID-19, which was declared a pandemic by the World Health Organization on March 11, 2020, has led to adverse impacts on the U.S. and global economies, disruptions of financial markets, and created uncertainty regarding potential impacts to the Company’s supply chain, operations, and customer demand. The COVID-19 pandemic has impacted and could further impact the Company’s operations and the operations of the Company’s suppliers and vendors as a result of quarantines, facility closures, and travel and logistics restrictions. Specifically, the Company attributes the pandemic to a delay in a planned financing which was to be used for the construction of the biotech complex, resulting in an impairment of the capitalized construction-in-progress at September 30, 2020. The extent to which the COVID-19 pandemic further impacts the Company’s business, results of operations and financial condition will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to the duration, spread, severity, and impact of the COVID-19 pandemic, the effects of the COVID-19 pandemic on the Company’s customers, suppliers, and vendors and the remedial actions and stimulus measures adopted by local and federal governments, and to what extent normal economic and operating conditions can resume. The management team is closely following the progression of COVID-19 and its impact on the Company. Even after the COVID-19 pandemic has subsided, the Company may continue to experience adverse impacts to its business as a result of any economic recession or depression that has occurred or may occur in the future. Therefore, the Company cannot reasonably estimate the impact at this time our business, liquidity, capital resources, and financial results.

 

2. Significant Accounting Policies

 

(a) Interim Financial Statements

 

These condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods shown. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period.

 

 
9

Table of Contents

 

PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

June 30, 2022

(Expressed in U.S. dollars)

(Unaudited)

 

2. Significant Accounting Policies (continued)

 

 

(b)

Basis of Presentation

 

 

 

 

 

The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States and are expressed in U.S. dollars. These condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, WFS Pharmagreen Inc. (“WFS”), and its 89.7% owned subsidiary 1155097 B.C. Ltd. (“115BC”), companies incorporated in British Columbia, Canada. All inter-company accounts and transactions have been eliminated. The Company’s fiscal year-end is September 30.

 

 

 

 

(c)

Use of Estimates and Judgments

 

 

 

 

 

The preparation of these condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the equity component of convertible notes, fair value of derivative liabilities, fair value of stock-based payments, and deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

 

 

 

 

 

The Company applies judgment in the application of the going concern assumption which requires management to take into account all available information about the future, which is at least, but not limited to, 12 months from the end of the reporting period.

 

 

 

 

(d)

Recently Adopted Accounting Pronouncements

 

 

 

 

 

The Company has implemented all new accounting pronouncements that are in effect and that may impact its condensed consolidated financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

 

3. Accounts Payable and Accrued Liabilities

 

Accounts payable and accrued liabilities consists of the following:

 

 

 

June 30,

2022

$

 

 

September 30,

2021

$

 

 

 

 

 

 

 

 

Accounts payable

 

 

621,933

 

 

 

579,851

 

Accrued interest payable

 

 

109,354

 

 

 

79,586

 

 

 

 

 

 

 

 

 

 

Balance

 

 

731,287

 

 

 

659,437

 

 

 
10

Table of Contents

  

PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

June 30, 2022

(Expressed in U.S. dollars)

(Unaudited)

 

4. Loans Payable

 

 

(a)

On November 22, 2019, the Company entered into a promissory note with an unrelated party for $40,000 in connection with an equity purchase agreement (Refer to Note 12(b)). The promissory note is unsecured, was due on November 30, 2020, and bears interest on the unpaid principal balance at a rate of 10% per annum. At June 30, 2022, the Company has recorded accrued interest payable of $10,399 (September 30, 2021 - $7,410) and the promissory note is in default. Refer to Note 12(l).

 

 

 

 

(b)

On April 22, 2020, the Company received a loan for Cdn$40,000 from the Government of Canada under the Canada Emergency Business Account program (“CEBA”). As at June 30, 2022, the balance owing is $31,049 (Cdn$40,000) (September 30, 2021 - $31,532 (Cdn$40,000)). These funds are interest free until December 31, 2023, at which time the remaining balance will convert to a 2-year term loan at an interest rate of 5% per annum. If the Company repays the loan prior to December 31, 2023, there will be loan forgiveness of 25% of the principal balance repaid, up to a maximum of Cdn$10,000.

 

5. Convertible Notes

 

 

(a)

On November 22, 2019, the Company entered into a promissory note with an unrelated party for $40,000 in connection with an equity purchase agreement (Refer to Note 12(b)). The promissory note is unsecured, was due on November 30, 2020, and bears interest on the unpaid principal balance at a rate of 10% per annum. At June 30, 2022, the Company has recorded accrued interest payable of $10,399 (September 30, 2021 - $7,410) and the promissory note is in default.  Refer to Note 12(l). 

 

 

 

 

 

During the year ended September 30, 2018, the Company issued 31,745,000 shares of common stock upon the conversion of $3,174 of Series A convertible notes, which included 18,000,000 common shares to the President of the Company and 5,320,000 common shares to family members of the President of the Company. Upon conversion, the Company immediately recognized the related remaining debt discount of $3,112 as accretion expense.

 

 

 

 

 

During the year ended September 30, 2019, the Company issued 3,900,000 shares of common stock upon the conversion of $390 of Series A convertible notes. Upon conversion, the Company immediately recognized the related remaining debt discount of $375 as accretion expense.

 

 

 

 

 

During the year ended September 30, 2020, the Company issued 18,525,000 shares of common stock upon the conversion of $1,853 of Series A convertible notes. Upon conversion, the Company immediately recognized the related remaining debt discount of $1,670 as accretion expense.

 

 

 

 

 

As at June 30, 2022, the carrying value of the convertible notes was $14,476 (September 30, 2021 – $7,834) and had an unamortized discount of $12,591 (September 30, 2021 - $19,233). During the nine months ended June 30, 2022, the Company recorded accretion expense of $6,642 (2021 - $2,923).

 

 
11

Table of Contents

 

PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

June 30, 2022

(Expressed in U.S. dollars)

(Unaudited)

 

5. Convertible Notes (continued)

 

 

(b)

On January 14, 2020, the Company entered into a convertible note with an unrelated party for $78,000, of which $3,000 was paid for financing costs, resulting in net proceeds to the Company of $75,000. The note was due on January 14, 2021, and bears interest on the unpaid principal balance at a rate of 12% per annum, which increases to 15% per annum upon default of the note. The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to lower of: 65% of the lowest trading price during the 20-trading day period prior to the issuance date; or (ii) 65% of the lowest trading price during the 20-trading day period prior to the conversion date. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $76,330. The Company recognized the maximum intrinsic value of the embedded beneficial conversion feature of $74,500, resulting in a loss on change in fair value of derivative liabilities of $1,830, and reduced the carrying value of the convertible note to $500. The carrying value will be accreted over the term of the convertible note up to its face value of $78,000.

 

 

 

 

 

The financing costs were netted against the convertible note and are being amortized over the term using the effective interest rate method. During the year ended September 30, 2020, the Company recognized accretion expense of $16,447.

 

 

 

 

 

During the year ended September 30, 2021, the Company issued 2,600,000 shares of common stock upon the conversion of $18,923 of the convertible note and $4,500 of conversion fees. On January 14, 2021, the Company failed to repay the note upon maturity and recorded additional default principal of $53,007.

 

 

 

 

 

As at June 30, 2022, the carrying value of the convertible note was $112,084 (September 30, 2021 - $112,084), and the fair value of the derivative liability was $163,760 (September 30, 2021 - $264,481).

 

 

 

 

(c)

On January 22, 2020, the Company entered into a convertible note with an unrelated party for $78,750, of which $9,750 was paid directly to third parties for financing costs, resulting in proceeds to the Company of $69,000. The note is due on January 22, 2021, and bears interest on the unpaid principal balance at a rate of 10% per annum, payable in common stock, which increases to 24% per annum upon default of the note. The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to 65% of the lowest trading price during the 20-trading day period ending on the latest complete trading day prior to the conversion date. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $75,179. The Company recognized the maximum intrinsic value of the embedded beneficial conversion feature of $68,500, resulting in a loss on change in fair value of derivative liabilities of $6,679, and reduced the carrying value of the convertible note to $500. The carrying value will be accreted over the term of the convertible note up to its face value of $78,750.

 

 

 

 

 

The financing costs were netted against the convertible note and are being amortized over the term using the effective interest rate method. During the year ended September 30, 2020, the Company defaulted on the convertible note and recognized accretion expense of $78,250. On January 22, 2021, the Company failed to repay the note upon maturity.

 

 

 

 

 

As at June 30, 2022, the carrying value of the convertible note was $78,750 (September 30, 2021 - $78,750) and the fair value of the derivative liability was $129,035 (September 30, 2021 - $207,522).

 

 
12

Table of Contents

 

PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

June 30, 2022

(Expressed in U.S. dollars)

(Unaudited)

 

5. Convertible Notes (continued)

 

 

(d)

On March 11, 2022, the Company entered into a convertible note with an unrelated party for $30,000, with an advance on January 18, 2022 for the full amount. The note is due on January 18, 2023, and bears interest on the unpaid principal balance at a rate of 10% per annum. The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to the closing price on the day of receiving the notice to convert. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $15,011, which reduced the carrying value of the convertible note to $14,989. The carrying value will be accreted over the term of the convertible note up to its face value of $30,000.

 

 

 

 

 

As at June 30, 2022, the carrying value of the convertible note was $19,195 (September 30, 2021 - $nil), had an unamortized discount of $10,805 (September 30, 2021 - $nil), and the fair value of the derivative liability was $13,796 (September 30, 2021 - $nil). During the nine months ended June 30, 2022, the Company recorded accretion expense of $4,206.

   

6. Derivative Liabilities

   

 

The embedded conversion option of the Company’s convertible notes described in Note 5 contain a conversion feature that qualifies for embedded derivative classification. The fair value of this liability will be re-measured at the end of every reporting period and the change in fair value will be reported in the statement of operations as a gain or loss on change in fair value of derivative liabilities. The table below sets forth a summary of changes in the fair value of the Company’s Level 3 financial liabilities:

   

Balance, September 30, 2021

 

 

472,003

 

 

 

 

 

 

Additions

 

 

15,011

 

Change in fair value of embedded conversion option

 

 

(180,423)

 

 

 

 

 

Balance, June 30, 2022

 

 

306,591

 

 

 

The Company uses Level 3 inputs for its valuation methodology for the embedded conversion option liabilities as their fair values were determined by using a binomial model based on various assumptions. Significant changes in any of these inputs in isolation would result in a significant change in the fair value measurement. As required, these are classified based on the lowest level of input that is significant to the fair value measurement. The following table shows the assumptions used in the calculations:

     

 

 

Expected

volatility

 

 

Risk-free interest rate

 

 

Expected dividend yield

 

 

Expected life (in years)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

As at March 11, 2022

 

 

149%

 

 

1.22%

 

 

0%

 

 

0.86

 

As at June 30, 2022

 

 

157%

 

 

2.51%

 

 

0%

 

 

0.50

 

 

7. Related Party Transactions

 

 

(a)

As at June 30, 2022, the Company owed $587,516 (Cdn$756,897) (September 30, 2021 - $547,079 (Cdn693,998)) to the President of the Company, which is non-interest bearing, unsecured, and due on demand. During the nine months ended June 30, 2022, the Company incurred consulting fees of $70,992 (2021 - $72,171) to the President of the Company.

 

 

 

 

(b)

As at June 30, 2022, the Company owed $57,052 (Cdn$73,500) (September 30, 2021 - $57,940 (Cdn$73,500)) to the father of the President of the Company, which is non-interest bearing, unsecured, and due on demand.

 

 

 

 

(c)

As at June 30, 2022, the Company owed $27,308 (Cdn$35,181) (September 30, 2021 – $26,960 (Cdn$34,200)) to a company owned by the father of the President of the Company, which is included in accounts payable and accrued liabilities. The amount due is non-interest bearing, unsecured, and due on demand.

   

 
13

Table of Contents

 

PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

June 30, 2022

(Expressed in U.S. dollars)

(Unaudited)

 

7. Related Party Transactions (continued)

 

 

(d)

As at June 30, 2022, the Company owed $506,538 (Cdn$652,573) (September 30, 2021 – $445,591 (Cdn$565,256)) to a company controlled by the Chief Financial Officer of WFS, which is included in accounts payable and accrued liabilities. The amount due is non-interest bearing, unsecured, and due on demand. During the nine months ended June 30, 2022, the Company incurred consulting fees of $70,992 (2021 - $72,171) to the company controlled by the Chief Financial Officer of WFS.

 

 

 

 

(e)

On June 1, 2022, the Company entered into a loan agreement with the father of the President of the Company with a principal of $50,000, which bears interest at 10% per annum, is unsecured and due on June 1, 2026.

 

 

 

 

(f)

On June 1, 2022, the Company entered into a loan agreement with the father of the President of the Company with a principal of $42,692 (Cdn$55,000), which bears interest at 10% per annum, is unsecured and due on June 1, 2026.

 

8. Common Stock

 

Nine months ended June 30, 2022

 

 

(a)

On October 21, 2021, the Company issued 4,000,000 shares of common stock at 0.025 per share for proceeds of $100,000. In connection with the financing, the Company incurred commission fees of $8,000.

 

 

 

 

(b)

On January 19, 2022, the Company issued 650,000 units at $0.01 per unit for proceeds of $6,500. Each unit is comprised of one share of common stock and one share purchase warrant exercisable at $0.05 per share of common stock expiring 24 months from the date of issuance.

 

 

 

 

(c)

On January 19, 2022, the Company issued 800,000 shares of common stock at $0.025 per share for proceeds of $20,000.

 

 

 

 

(d)

On January 19, 2022, the Company issued 6,800,000 shares of common stock with a fair value of $136,000 for consultation communication and media services (Note 12(g)).

 

 

 

 

(e)

On January 19, 2022, the Company issued 1,800,000 shares of common stock with a fair value of $36,000 for strategic and business development advisory services (Note 12(h)).

 

 

 

 

(f)

On January 21, 2022, the Company issued 1,000,000 shares with a fair value of $19,700 for management consulting and strategic business advisory services (Note 12(f)).

 

 

 

 

(g)

On February 10, 2022, the Company issued 1,000,000 shares of common stock with a fair value of $17,000 for market awareness services (Note 12(i)).

 

 

 

 

(h)

On May 3, 2022, the Company issued 7,000,000 shares of common stock with a fair value of $84,700 for market awareness services (Note 12(j)).

 

 

 

 

(i)

On June 8, 2022, the Company issued 20,200,000 units at $0.0025 per unit for proceeds of $68,500. Each unit is comprised of one share of common stock and one purchase warrant exercisable at $0.05 per share of common stock expiring 24 months from the date of issuance.

 

9. Preferred Stock

 

 

On October 13, 2020. The Company filed a certificate of amendment to its articles of incorporation, whereby it increased the authorized capital to 2,000,000,000 shares of common stock with a par value of $0.001 per share and 1,000,000 preferred shares with a par value of $0.001. On October 14, 2020, the Company designated 10,000 preferred shares as Series A Super Voting Preferred Stock.

 

 

 

The Series A Super Voting Preferred Stock has the following rights and restrictions:

 

 

 

Dividends - Initially, there will be no dividends due or payable on the Series A Super Voting Preferred Stock. Any future terms with respect to dividends shall be determined by the Board consistent with the Corporation’s Certificate of Incorporation. Any and all such future terms concerning dividends shall be reflected in an amendment to this Certificate, which the Board shall promptly file or cause to be filed.

 

 

 

Liquidation and Redemption Rights - Upon the occurrence of a Liquidation Event, the holders of Series A Super Voting Preferred Stock are entitled to receive net assets on a pro-rata basis. Each holder of Series A Super Voting Preferred Stock is entitled to receive ratably any dividends declared by the Board, if any, out of funds legally available for the payment of dividends.

 

 
14

Table of Contents

 

PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

June 30, 2022

(Expressed in U.S. dollars)

(Unaudited)

 

9. Preferred Stock (continued)

 

Rank - All shares of the Series A Super Voting Preferred Stock shall rank (i) senior to the Corporation’s (A) Common Stock, par value $0.001 per share ( “Common Stock” ), and any other class or series of capital stock of the Corporation hereafter created, except as otherwise provided in clauses (ii) and (iii) of this Section 4, (ii) pari passu with any class or series of capital stock of the Corporation hereafter created and specifically ranking, by its terms, on par with the Series A Super Voting Preferred-Stock and (iii) junior to any class or series of capital stock of the Corporation hereafter created specifically ranking, by its terms, senior to the Series A Preferred Stock, in each case as to distribution of assets upon liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary.

 

Voting Rights - If at least one share of Series A Super Voting Preferred Stock is issued and outstanding, then the total aggregate issued shares of Series A Super Voting Preferred Stock at any given time, regardless of their number, shall have voting rights equal to 20 times the sum of: i) the total number of shares of Common stock which are issued and outstanding at the time of voting, plus ii) the total number of shares of all Series of Preferred stocks which are issued and outstanding at the time of voting.

 

Each individual share of Series A Super Voting Preferred Stock shall have the voting rights equal to:

 

 

·

[twenty times the sum of: {all shares of Common stock issued and outstanding at the time of voting + all shares of Series A, Series A and any newly designated Preferred stock issued and outstanding at the time of voting}] Divided by:

 

 

 

 

·

[the number of shares of Series A Super Voting Preferred Stock issued and outstanding at the time of voting]

 

With respect to all matters upon which stockholders are entitled to vote or to which stockholders are entitled to give consent, the holders of the outstanding shares of Series A Super Voting Preferred Stock shall vote together with the holders of Common Stock without regard to class, except as to those matters on which separate class voting is required by applicable law or the Certificate of Incorporation or Bylaws.

 

Protective Provisions - So long as any shares of Series A Super Voting Preferred Stock are outstanding, the Corporation shall not, without first obtaining the unanimous written consent of the holders of Series A Super Voting Preferred Stock, alter or change the rights, preferences or privileges of the Series A Super Voting Preferred so as to affect adversely the holders of Series A Super Voting Preferred Stock.

 

On October 14, 2020, the Company issued 10,000 shares of Series A Super Voting Preferred Stock to a Director of the Company for proceeds of $10. In connection with the issuance of the Series A Super Voting Preferred Stock, the Company evaluated whether the preferred stock should be classified as a liability based on the guidance under ASC 480, Distinguishing Liabilities from Equity. The Series A Super Voting Preferred Stock are not considered mandatorily redeemable, are not settleable in a variable number of shares, and do not contain any features embedded that required a separate assessment. As a result, the Company determined the Series A Super Voting Preferred Stock were not a liability and classified the preferred stock within equity in the amount of the aggregate par value of the issued shares of preferred stock, with any excess attributed to additional paid-in capital.

 

10. Share Purchase Warrants

 

The following table summarizes the continuity of the Company’s share purchase warrants:

 

 

 

Number of

warrants

 

 

Weighted average exercise price

$

 

 

 

 

 

 

 

 

Balance, September 30, 2021

 

 

37,986,786

 

 

 

0.05

 

 

 

 

 

 

 

 

 

 

Issued

 

 

20,850,000

 

 

 

0.05

 

 

 

 

 

 

 

 

 

 

Balance, June 30, 2022

 

 

58,836,786

 

 

 

0.05

 

 

 
15

Table of Contents

 

PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

June 30, 2022

(Expressed in U.S. dollars)

(Unaudited)

  

10. Share Purchase Warrants (continued)

 

Number of warrants

 

 

Exercise price

 

 

 Expiry date

 

 

 

 

 

 

 

 

 

 

114,286

 

 

$

0.55

 

 

July 16, 2022

 

 

400,000

 

 

$

0.05

 

 

December 2, 2022

 

 

3,000,000

 

 

$

0.05

 

 

December 11, 2022

 

 

2,000,000

 

 

$

0.05

 

 

December 30, 2022

 

 

2,300,000

 

 

$

0.05

 

 

January 11, 2023

 

 

13,500,000

 

 

$

0.05

 

 

January 30, 2023

 

 

1,000,000

 

 

$

0.05

 

 

February 16, 2023

 

 

611,250

 

 

$

0.05

 

 

March 1, 2023

 

 

6,961,250

 

 

$

0.05

 

 

May 14, 2023

 

 

6,100,000

 

 

$

0.05

 

 

August 25, 2023

 

 

2,000,000

 

 

$

0.05

 

 

September 24, 2023

 

 

650,000

 

 

$

0.05

 

 

January 19, 2024

 

 

20,200,000

 

 

$

0.05

 

 

June 8, 2024

 

 

 

 

 

 

 

 

 

 

 

 

58,836,786

 

 

 

 

 

 

 

 

 

11. Memorandum of Understanding

 

On July 25 2021, the Company entered into a Memorandum of Understanding (“MOU”) to acquire all the assets and cannabis business operation, including 12 acres of property, structure and cannabis licenses, existing sales channels and distribution networks, from a private company situated in Northern California. Upon reaching a definitive agreement, the Company intends to further develop a state- of-the-art flowering greenhouse of approximately 12,000 square feet or the maximum allowed by California State and Regional County. The acquisition price is $2,400,000 to be paid through a combination of cash and shares. The Company also has an option from the seller to acquire an additional 120 acres or more of land for business expansion and development. As at June 30, 2022, the Company has advanced $87,100 (September 30, 2021 - $nil) under the MOU, which will be applied against the final purchase price upon completion of a definitive agreement. This amount has been included in prepaid expenses and deposits. The Company currently lacks funds with which to consummate the contemplated transaction and has not negotiated a definitive agreement with respect to the contemplated transaction. Thus, there is no assurance that the Company will ever enter into, and consummate, a definitive agreement with respect to the contemplated transaction.

 

12. Commitments and Contingency

 

 

(a)

Effective December 11, 2017, the Company entered into a binding Letter of Intent (“LOI”) with Alliance Growers Corp. (“Alliance”), whereby the Company will build a new cannabis biotech complex located in Deroche, British Columbia, through their subsidiary, 115BC. On January 25, 2019, the Company’s subsidiaries WFS and 115BC entered into an option agreement with Alliance, which superseded the LOI entered into on December 11, 2017. The option agreement grants an option to Alliance to purchase 10% equity interest in 115BC for Cdn$1,350,000 and previously granted a second option to purchase an additional 20% equity interest in 115BC for funding of 30% of the total construction and equipment costs for the biotech complex less Cdn$1,350,000. On January 25, 2019, 115BC issued 8 shares of common stock to Alliance upon exercise of the first option for consideration of $1,018,182 (Cdn$1,350,008), which was recognized as additional paid-in capital. The second option expired unexercised. As at June 30, 2022, the Company received advances of $58,216 (Cdn$75,000) (September 30, 2021 - $59,122 (Cdn$75,000)) from Alliance, which is unsecured, non-interest bearing, and due on demand.

  

 
16

Table of Contents

 

PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

June 30, 2022

(Expressed in U.S. dollars)

(Unaudited)

  

12. Commitments and Contingency (continued)

 

 

(b)

On November 22, 2019, the Company entered into an equity purchase agreement with an unrelated party, whereby the third party is to purchase up to $10,000,000 of the Company’s common stock. The equity purchase agreement is effective for a term of 2 years from the effective date of the registration statement. The purchase price would be 85% of the market price. In return, the Company issued a promissory note of $40,000 (Refer to Note 4(a)). In addition, the Company is required to pay an additional commitment fee of $10,000, of which $5,000 was paid upon signing the term sheet and the remaining $5,000 is due upon completion of the first tranche of the financing.

 

 

 

 

(c)

Effective May 14, 2021, the Company entered into a Software as a Service Agreement with Novation Solutions Inc. (“DealMaker”) to effect the Company’s planned Regulation A offering, including the set-up of an automated tracking, signing, and reconciliation portal. The Company will pay DealMaker $3,000 upon signing the agreement, $7,000 30 days prior to launching the portal, and a post launch monthly fee of $1,000. The monthly fee will automatically renew each month for the shorter of the duration of the offering period, or one year.

 

 

 

 

(d)

Effective August 23, 2021, the Company entered into an infomercial production and broadcast agreement with New to the Street Group LLC. Pursuant to the terms of the agreement, New to the Street Group LLC will provide investor relations and consulting services in consideration for 6,000,000 shares of common stock for the first 3 months and, at the option of the Company, at $40,000 per month for a further 9 months, which can be paid in cash or shares of common stock at the Company’s discretion. On September 22, 2021, the Company issued 6,000,000 shares of common stock with a fair value of $210,000. During the nine months ended June 30, 2022, the Company recognized consulting fees of $210,000 pursuant to the agreement. As at June 30, 2022, the Company has recognized $nil (September 30, 2021 – $188,137) in prepaid expenses and deposits.

 

 

 

 

(e)

Effective August 27, 2021, the Company entered into a consulting agreement for investor relations and consulting services for a period of 6 months. Pursuant to the agreement, the Company agreed to issue shares of common stock of the Company with a fair value of $100,000. On September 22, 2021, the Company issued 4,340,000 shares of common stock with a fair value of $147,560. During the nine months ended June 30, 2022, the Company recognized consulting fees of $95,763 pursuant to the agreement. As at June 30, 2022, the Company has recognized $nil (September 30, 2021 – $95,763) in prepaid expenses and deposits.

 

 

 

 

(f)

On January 12, 2022, the Company entered into a consulting agreement with a six-month term. Pursuant to the agreement, the Company agreed to issue 1,000,000 shares of common stock in exchange for management consulting and strategic business advisory services. On January 21, 2022, the Company issued a total of 1,000,000 shares of common stock with a fair value of $19,700 pursuant to the agreement (Note 8(f)). As at June 30, 2022, the Company recognized $1,305 (September 30, 2021 - $nil) in prepaid expenses and deposits. During the nine months ended June 30, 2022, the Company recognized consulting fees of $18,395 (2021 - $nil) pursuant to the agreement.

 

 

 

 

(g)

On January 18, 2022, the Company entered into a consulting agreement with a six-month term. Pursuant to the agreement, the Company agreed to issue shares of common stock of the Company with a fair value of Cdn$100,000 in exchange for consultation communication and media services. In addition, the Company may choose to pay a bonus if certain predetermine milestones is met during the term of the agreement. On January 19, 2022, the Company issued a total of 6,800,000 shares of common stock with a fair value of $136,000 pursuant to the agreement (Note 8(d)). As at June 30, 2022, the Company recognized $13,525 (September 30, 2021 - $nil) in prepaid expenses and deposits. During the nine months ended June 30, 2022, the Company recognized consulting fees of $122,475 (2021 - $nil) pursuant to the agreement.

 

 

 

 

(h)

On January 18, 2022, the Company entered into a consulting agreement with a six-month term. Pursuant to the agreement, the Company agreed to issue 1,800,000 shares of common stock in exchange for strategic and business development advisory services. On January 19, 2022, the Company issued a total of 1,800,000 shares of common stock with a fair value of $36,000 pursuant to the agreement (Note 8(e)). As at June 30, 2022, the Company recognized $3,580 (September 30, 2021 - $nil) in prepaid expenses and deposits. During the nine months ended June 30, 2022, the Company recognized consulting fees of $32,420 (2021 - $nil) pursuant to the agreement.

   

12. Commitments and Contingency (continued)

 

 

(i)

On February 7, 2022, the Company entered into a consulting agreement with a six-month term. Pursuant to the agreement, the Company agreed to issue 1,000,000 shares of common stock in exchange for market awareness services. On February 10, 2022, the Company issued a total of 1,000,000 shares of common stock with a fair value of $17,000 pursuant to the agreement (Note 8(g)). As at June 30, 2022, the Company recognized $3,852 (September 30, 2021 - $nil) in prepaid expenses and deposits. During the nine months ended June 30, 2022, the Company recognized consulting fees of $13,148 (2021 - $nil) pursuant to the agreement.

 

 

 

 

(j)

On May 2, 2022, the Company entered into a consulting agreement with a six-month term. Pursuant to the agreement, the Company agreed to issue 7,000,000 shares of common stock in exchange for market awareness services. On May 3, 2022, the Company issued 7,000,000 shares of common stock with a fair value of $84,700 pursuant to the agreement (Note 8(h)). As at June 30, 2022, the Company recognized $57,230 (September 30, 2021 - $nil) in prepaid expenses and deposits. During the nine months ended June 30, 2022, the Company recognized consulting fees of $27,470 (2021 - $nil) pursuant to the agreement.

 

 

 

 

(k)

On May 20, 2022, the Company entered into a consulting agreement with a six-month term. Pursuant to the agreement, the Company agreed to issue 9,000,000 shares of common stock in exchange for public relations and communications services. If both parties agree to continue the agreement for another 6 months, the Company will issue common stock of the Company with a fair value of $80,000. As at June 30, 2022, the shares of common stock have not been issued and the Company recognized $18,692 (September 30, 2021 - $nil) in common stock issuable. During the nine months ended June 30, 2022, the Company recognized consulting fees of $18,692 (2021 - $nil) pursuant to the agreement.

 

 

 

 

(l)

On March 10, 2021, a noteholder filed a Notice of Motion for Summary Judgement in Lieu of Complaint (the “Notice”) with the State of New York Supreme Court, County of New York for $40,504 plus interest at the rate of 10% per annum from January 6, 2021, plus costs. On July 31, 2021, the Notice was dismissed without prejudice by the State of New York Supreme Court. On September 23, 2021, the noteholder filed a new Notice of Motion for Summary Judgement in Lieu of Complaint with the State of New York Supreme Court, County of New York for $44,504 plus interest at the rate of 10% per annum from January 6, 2021, plus costs. The plaintiff filed for an oral argument to be heard by the State of New York Supreme Court on September 15, 2022. The Company believes that the claim has no merit and intends to defend its position vigorously.

    

 
17

Table of Contents

   

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

Forward-Looking Statements

 

This section of the Form 10-Q includes a number of forward-looking statements that reflect our current views with respect to future events and financial performance. Forward-looking statements are often identified by words like believe, expect, estimate, anticipate, intend, project and similar expressions, or words which, by their nature, refer to future events. You should not place undue certainty on these forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our predictions.

 

Company History Overview

 

Pharmagreen Biotech Inc. (“the Company”) was incorporated under the laws of Nevada, U.S. on November 26, 2007 under the name Azure International, Inc. On October 30, 2008 and effective as of the same date, the Company filed Articles of Merger with the Secretary of the State of Nevada, to effect a merger by and between Air Transport Group Holdings, Inc., a Nevada corporation incorporated on October 16, 2008, and Azure International, Inc. As a result of the merger, the Company changed its name to Air Transport Group Holdings, Inc.

 

On April 12, 2018, the Company entered into a share exchange agreement with WFS Pharmagreen Inc., a private company incorporated under the laws of British Columbia, Canada, whereby the Company acquired all of the issued and outstanding shares of WFS Pharmagreen Inc. in exchange for 37,704,500 shares of common stock of the Company. Upon completion of this transaction, the shareholders of WFS Pharmagreen hold 95.5% of voting control of the Company.

 

Immediately prior to closing of the Agreement, the majority shareholder of the Company was also the majority shareholder of WFS. As a result of the common ownership upon closing of the transaction, the acquisition was considered a common-control transaction and was outside the scope of the business combination guidance in ASC 805-50. The entities are deemed to be under common control as of February 27, 2018, which was the date that the majority shareholder acquired control of the Company and, therefore, held control over both companies. On May 2, 2018, the Share Exchange Agreement was effected. In connection with this transaction, the Company changed its name on May 8, 2018 to Pharmagreen Biotech Inc. and changed its year end from April 30th to September 30th.

 

Our principal executive offices are temporarily located at 2987 Blackbear Court, Coquitlam, British Columbia, Canada. Our telephone number is (702-803-9404). Our internet address is www.pharmagreen.ca.

 

On August 7, 2020, our company (including subsidiaries) filed voluntary petitions under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Nevada, Case No. 20-13886.

 

On October 9, 2020, a stay order was lifted by a United States District Judge of the United States District Court for the Southern District of New York, on an action filed by a lender. This effectively removed the Company from its Chapter 11 bankruptcy proceedings and protection.

 

We expect to continue to incur losses for at least the next 12 months. We do not expect to generate revenue that is sufficient to cover our expenses, and we do not have sufficient cash and cash equivalents to execute our plan of operations for at least the next twelve months. We will need to obtain additional financing, through equity security sales, debt instruments and private financing, to conduct our day-to-day operations, and to fully execute our business plan. We plan to raise the capital necessary to fund our business through the sale of equity securities, debt instruments or private financing. These factors raise substantial doubt upon the Company’s ability to continue as a going concern. This report does not reflect all the adjustments that may be necessary if the Company is unable to continue as a going concern.

 

 
18

Table of Contents

 

Our Current Business

 

Pharmagreen Biotech Inc. (the “Company”) was incorporated under the laws of the State of Nevada on November 26, 2007. The Company is headquartered in Coquitlam, British Columbia. The Company’s mission is to advance the technology of tissue culture science and to provide the highest quality 100% germ free, disease free and all genetically the same plantlets of high CBD hemp and other flora and offering full spectrum DNA testing for plant identification, live genetics preservation using low temperature storage for various cannabis and horticulture plants; extraction of botanical oils mainly CBD oil, and to deliver laboratory based services to the North American high CBD hemp, Cannabis and agriculture sectors.

 

Management cannot provide assurance that the Company will ultimately achieve profitable operations or become cash flow positive, or raise additional debt and/or equity capital. However, if the Company is unable to raise additional capital in the near future, due to the Company’s liquidity problems, management expects that the Company will need to curtail operations, liquidate assets, seek additional capital on less favourable terms and/or pursue other remedial measures. These consolidated financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

The Company has decided that immediate business development in the hemp industry provides a much greater opportunity in the United States. The project at Deroche has been placed on hold while the Company moves forward to build out a similar infrastructure planned for Deroche within the United States.

 

On July 25, 2021, the Company entered into a Memorandum of Understanding to acquire all the assets and cannabis business operations (includes 12 acres property, structure and cannabis licenses, existing sales channels and distribution networks) from a private company situated in Northern California. Upon reaching a definitive agreement, the Company intends to further develop a state-of-the-art flowering greenhouse of approximately 12,000 square feet or the maximum allowed by California State and Regional County. The acquisition price is $2.4 million to be paid through a combination of cash and shares. The Company also has an option from the seller to acquire an additional 120 acres or more of land for business expansion and development. The Company currently lacks funds with which to consummate the contemplated transaction and has not negotiated a definitive agreement with respect to the contemplated transaction. Thus, there is no assurance that the Company will ever enter into, and consummate, a definitive agreement with respect to the contemplated transaction.

 

The outbreak of the novel coronavirus COVID-19, which was declared a pandemic by the World Health Organization on March 11, 2020, has led to adverse impacts on the U.S. and global economies, disruptions of financial markets, and created uncertainty regarding potential impacts to the Company’s supply chain, operations, and customer demand. The COVID-19 pandemic has impacted and could further impact the Company’s operations and the operations of the Company’s suppliers and vendors as a result of quarantines, facility closures, and travel and logistics restrictions. Specifically, the Company attributes the pandemic to a delay in a planned financing which was to be used for the construction of the biotech complex, resulting in an impairment of the capitalized construction-in-progress at September 30, 2020. The extent to which the COVID-19 pandemic further impacts the Company’s business, results of operations and financial condition will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to the duration, spread, severity, and impact of the COVID-19 pandemic, the effects of the COVID-19 pandemic on the Company’s customers, suppliers, and vendors and the remedial actions and stimulus measures adopted by local and federal governments, and to what extent normal economic and operating conditions can resume. The management team is closely following the progression of COVID-19 and its impact on the Company. Even after the COVID-19 pandemic has subsided, the Company may continue to experience adverse impacts to its business as a result of any economic recession or depression that has occurred or may occur in the future. Therefore, the Company cannot reasonably estimate the impact at this time our business, liquidity, capital resources, and financial results.

 

Capital Resources and Liquidity

    

Our auditors have issued a “going concern” opinion, meaning that there is substantial doubt if we can continue as an on-going business unless we obtain additional capital. No substantial revenues from our planned business model are anticipated until we have completed financing the Company. As at June 30, 2022, the Company has a working capital deficit of $1,799,521 and an accumulated deficit of $12,464,499. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

   

 
19

Table of Contents

 

We need to seek capital from resources such as the sale of private placements in the Company’s common stock or debt financing, which may not even be available to the Company. However, if such financing were available, because we are a, early-stage company with no or limited operations to date, it would likely have to pay additional costs associated with such financing and in the case of high risk loans be subject to an above market interest rate. At such time these funds are required, management would evaluate the terms of such financing. If the Company cannot raise additional proceeds via such financing, it may be required to cease business operations.

 

As of June 30, 2022, we had $24,262 in cash, amounts receivable of $316, and prepaid expenses and deposits of $166,592, as compared to $25,300 in cash, amounts receivable of $290 and prepaid expenses and deposits of $347,491 as of September 30, 2021. As of the date of this Form 10-Q, the current funds available to the Company will not be sufficient to fund the expenses related to maintaining our planned operations. We are in the process of seeking additional equity financing in the form of private placements, loans and registration statements to fund our intended business operations.

 

Management believes that if subsequent private placements are successful or we are successful in raising funds from registered securities, we will generate sales revenue within twelve months thereof. However, additional equity financing may not be available to us on acceptable terms or at all, and thus we could fail to satisfy our future cash requirements.

 

We do not anticipate researching any further products nor the purchase or sale of any significant equipment. We also do not expect any significant additions to the number of employees.

 

Results of Operations

 

Three Months Ended June 30, 2022

 

We had no revenue for the three months ended June 30, 2022 and 2021.

 

Operating expenses in the three months ended June 30, 2022 were $241,218 which was consistent with operating expenses for the three months ended June 30, 2021 of $232,380.

 

We earned a comprehensive income of $292,820 during the three months ended June 30, 2022, compared to a comprehensive loss of $155,360 during the three months ended June 30, 2021. The increase in comprehensive income in 2022 was mainly attributable to a change in fair value of derivative liabilities from a gain of $101,418 in 2021 to a gain of $510,066 in 2022, which resulted from fluctuations of the derivative liability due to the floating rates attached to the conversion rights to the convertible debt.

 

During the three months ended June 30, 2022 and 2021, we recognized net income of $251,935 and a net loss of $142,145, respectively.

 

Nine Months Ended June 30, 2022

 

We had no revenue for the nine months ended June 30, 2022 and 2021.

 

Operating expenses in the nine months ended June 30, 2022 were $903,738 as compared to operating expenses for the nine months ended June 30, 2021 of $470,953. The net increase in expenses during the current period is mainly due to an increase in consulting fees from $296,987 in 2021 to $761,972 in 2022, which was mainly related various infomercial production agreements, management consulting and strategic business advisory services consulting agreements entered into, and an increase in foreign exchange loss from a gain of $16,951 in 2021 to a loss of $9,229 in 2022.

 

 
20

Table of Contents

 

We incurred a comprehensive loss of $744,130 during the nine months ended June 30, 2022, compared to a comprehensive loss of $3,769,058 during the nine months ended June 30, 2021. The decrease in comprehensive loss in 2022 was mainly attributable to a change in fair value of derivative liabilities from a loss of $3,083,420 in 2021 to a gain of $180,423 in 2022, as we had significantly more convertible debt in the prior year which resulted in more fluctuations of the derivative liability due to the floating rates attached to the conversion rights to the convertible debt and a decrease in interest and finance costs from $673,124 in 2021 to $30,919 in 2022 due to a lower overall face value of outstanding convertible debentures in the current period compared to last year. The decreases were offset by a gain of $613,526 for a settlement of convertible notes in 2021 that was a one-time settlement.

 

During the nine months ended June 30, 2022 and 2021, we incurred a net loss of $765,082 and $3,700,644 respectively.

 

Off-balance Sheet Arrangements

 

The Company has no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect or change on the company’s financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors. The term “off-balance sheet arrangement” generally means any transaction, agreement or other contractual arrangement to which an entity unconsolidated with the company is a party, under which the company has (i) any obligation arising under a guarantee contract, derivative instrument or variable interest; or (ii) a retained or contingent interest in assets transferred to such entity or similar arrangement that serves as credit, liquidity or market risk support for such assets.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

  

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

 

Item 4. Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures

 

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time period specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 is accumulated and communicated to management including our principal executive officer and principal financial officer as appropriate, to allow timely decisions regarding required disclosure.

 

In connection with this quarterly report, as required by Rule 15d-15 under the Securities Exchange Act of 1934, we have carried out an evaluation of the effectiveness of the design and operation of our company’s disclosure controls and procedures. This evaluation was carried out under the supervision and with the participation of our company’s management, including our company’s principal executive officer and principal financial officer. Based upon that evaluation, our company’s principal executive officer and principal financial officer concluded that as of June 30, 2022 our disclosure controls and procedures were not effective due to the existence of material weaknesses in our internal controls over financial reporting.

 

Changes in Internal Control Over Financial Reporting

 

There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) or 15d-15(f)) during the quarter ended June 30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

 

Sadler Gibb & Associates LLC, our independent auditors, are not required to and have not performed an assessment of our internal controls over financial reporting.

 

 
21

Table of Contents

 

PART II—OTHER INFORMATION

 

Item 1. Legal Proceedings.

  

On July 22, 2020, the Company received a preliminary statement of claim from a convertible note holder for failure of the Company to deliver shares of common stock upon receipt of notices of conversion. Pursuant to the claim, the plaintiff has requested receipt of all shares of common stock requested in the notices of conversion, and also damages in an amount to be determined at trial but in any event in excess of principal amount of $78,000 for a total sum of $180,000, including without limitation the balance of any portion of the convertible note that ultimately is not converted into shares of common stock, along with default interest, liquidated damages, and damages as provided for in the convertible note.

  

On October 9, 2020, a stay order was lifted by a United States District Judge of the United States District Court for the Southern District of New Y